Men Treated for Localized Prostate Cancer Could Benefit From Pomegranate Juice Consumption
Posted on: Monday, 27 April 2009, 09:22 CDT
LINTHICUM, Md.,
The two-stage clinical trial followed a total of 48 participants over six years. Eligible participants had a rising PSA after surgery or radiotherapy, a PSA greater than 0.2 ng/ml and less than 5 ng/ml and a Gleason score of 7 or less. These patients were treated by drinking eight ounces of pomegranate juice daily. Currently, in the sixth year of treatment, active patients who remain on the study have a median total follow-up of 56 months. These participants continue to experience a significant increase in PSA doubling time following treatment, from a mean of 15.4 months at baseline to 60 months post-treatment, with a median PSA slope decrease of 60 percent, 0.06 to 0.024.
Researchers compared active patients, who remain on the study, with non-active patients, who no longer remain on the study. Though these two groups demonstrated similar mean PSA doubling times at baseline, both the PSA doubling time prolongation and the decline in median PSA slope were greater in active patients when compared to non-active patients.
"This study suggests that pomegranate juice may effectively slow the progression of prostate cancer after unsuccessful treatment," said
Parts of this ongoing study suggest that some patients may be more sensitive to the effects of pomegranate juice on PSA doubling time. Phase three of this study is currently underway to further evaluate the benefits of pomegranate juice in a placebo-controlled manner.
NOTE TO REPORTERS: Experts are available to discuss these studies outside normal briefing times. To arrange an interview with an expert, please contact the AUA Communications Office at the number below or e-mail
Pantuck, A; Zomorodian, N; Rettig, M; Aronson, W; Heber, D; Belldegrun, A. Long term follow up of phase 2 study of pomegranate juice for men with prostate cancer shows durable prolongation of PSA doubling time. J Urol, suppl. 2009: 181, 4, abstract 826.
About the American Urological Association: Founded in 1902 and headquartered near
SOURCE American Urological Association
Source: PR Newswire
Related Articles
- First Pediatric Patient Treated With Aptocine(TM), a Novel Light-Activated Drug, in Neurofibromatosis Study
- Committee for Medicinal Products for Human Use (CHMP) Recommends Granting Marketing Authorisation for FIRMAGON(R) (degarelix) for Treatment of Prostate Cancer
- RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
- New Studies Unveiled at ASTRO's 49th Annual Meeting of Radiation Oncology Specialists Support the Effectiveness of IsoRay Medical's Proxcelan(TM) for the Treatment of Prostate Cancer
- Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
- False beliefs affect treatment of prostate cancer
- Study Eyes Obesity-Prostate Cancer Link
- New Hope For Prostate Cancer Patients Where Radiation Treatment Has Failed
- Community Care Physicians of Latham, New York Deliver Ultra-Precise Image-Guided Radiotherapy Treatments for Prostate Cancer Patients
- New Study Confirms Value of Vitamin D Supplementation in the Adjunctive Treatment of Prostate Cancer
User Comments (0)

RSS Feeds